XORTX Therapeutics Inc.
XRTX.V
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.87% | -18.58% | 4.23% | 5.50% | -9.19% |
| Depreciation & Amortization | -19.00% | 6.97% | 56.97% | 3.13% | -51.95% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.68% | -32.68% | -45.32% | -37.26% | -63.12% |
| Operating Income | -27.68% | 32.68% | 45.32% | 37.26% | 63.12% |
| Income Before Tax | 76.86% | -95.46% | 55.98% | 110.05% | -64.79% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 76.86% | -95.46% | 55.98% | 110.05% | -64.79% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.86% | -95.46% | 55.98% | 110.05% | -64.79% |
| EBIT | -27.68% | 32.68% | 45.32% | 37.26% | 63.12% |
| EBITDA | -33.25% | -21.95% | 45.42% | 39.14% | 63.58% |
| EPS Basic | 84.95% | -97.23% | 69.69% | 106.92% | -30.88% |
| Normalized Basic EPS | 84.96% | -97.23% | 69.68% | 106.92% | -30.89% |
| EPS Diluted | 84.71% | -97.24% | 69.82% | 106.89% | -30.81% |
| Normalized Diluted EPS | 84.96% | -97.23% | 69.68% | 106.92% | -30.89% |
| Average Basic Shares Outstanding | 53.83% | 63.88% | 45.27% | 45.27% | 25.91% |
| Average Diluted Shares Outstanding | 53.83% | 63.88% | 45.27% | 45.27% | 25.91% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |